Pulmonary Alveolar Microlithiasis: A Review of a Rare Disease Through Rarely Discussed Perspectives

Area of Science:

• Pulmonary Medicine
• Genetics
• Rare Diseases

Background:

• Pulmonary alveolar microlithiasis (PAM) is an ultrarare lung disease with established descriptions and genetics but no effective treatments.
• Mutations in the sodium-phosphate co-transporter gene SLC34A2 are linked to PAM, offering a potential therapeutic target.
• The variable clinical course and clinico-radiological dissociation in PAM highlight the need for better understanding and management strategies.

Purpose of the Study:

• To review the current understanding of Pulmonary Alveolar Microlithiasis (PAM).
• To emphasize the need for developing a disease severity score for PAM.
• To advocate for international registries and standardized data collection for PAM research.

Main Methods:

• Literature review of Pulmonary Alveolar Microlithiasis (PAM).
• Analysis of genetic factors, specifically SLC34A2 mutations.
• Discussion on the development of a composite disease severity score and standardized data collection methods.

Main Results:

• No effective prevention or treatment for PAM is currently established.
• Ongoing identification of SLC34A2 variants necessitates a broader genetic understanding.
• A composite disease severity score and standardized data collection are identified as critical needs.

Conclusions:

• Further research into SLC34A2 mutations could guide novel therapeutic development for PAM.
• A composite disease severity score is essential for patient stratification and research design in PAM.
• International collaboration, registries, and standardized data collection are urgently required to advance clinical care for PAM.